Alternative therapeutics for pulmonary hypoplasia that either do not interact with heparin, or alternative anticoagulants which do not interact with angiogenic factors such as VEGF, deserve further expedient investigation to treat this often-fatal disease. The gene discussed is VEGFA; the disease is Pulmonary hypoplasia.